News

NBC4 Columbus15d
e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
In the leading Gubra‑Amylin NASH diet‑induced obese (GAN‑DIO) mouse model, ETX‑312 demonstrated: Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in ...
manilatimes14d
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Enhanced safety: Diet-induced obesity ("DIO”) mouse model data highlighted the sufficiency of the highly-peripherally restricted CB1 inhibitor nimacimab--without central (brain) exposure--to drive ...
Taiwan News16d
e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
Title: ETX-312, a GalOmic siRNA for the treatment of MASH, effectively improves the MASH phenotype of GAN DIO-MASH mice alone or in combination with emerging therapies Poster Number: FRI-337 Date: 9 ...